The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Kaken, Dong-Wha Ink License Pact for Ecclock in South Korea
Kaken Pharmaceutical said on June 2 that it has concluded an exclusive distribution agreement in South Korea with local partner Dong-Wha Pharm for its primary axillary hyperhidrosis treatment Ecclock (sofpironium bromide).Under the deal, signed on June 1, the Japanese company…
To read the full story
Related Article
- Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
September 3, 2025
- Hyperhidrosis Drug Ecclock Filed in South Korea: Kaken
October 6, 2023
BUSINESS
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…